Search results for "medicine.drug_mechanism_of_action"

showing 3 items of 13 documents

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil.

2009

Abstract Cigarette smoke mediated oxidative stress and endothelial dysfunction are important processes in the pathogenesis of several lung disorders. In this study we evaluated the effect of PDE5 inhibition on pulmonary artery endothelial dysfunction induced by cigarette smoke in vitro . Human pulmonary artery endothelial cells (HPAEC) were incubated in the absence or presence of PDE5 inhibitor sildenafil (10 nM–1 μM), PKG agonist 8-Br-cGMP (1 mM), or the antioxidants dyphenyleneiodonium (DPI 1 μM) and N -acetylcysteine (NAC 1 mM) for 30 min. Then, cigarette smoke extract (CSE) was added for 24 h. CSE (2.5–10%)-induced ROS generation was suppressed by DPI, and partially reversed by sildenaf…

medicine.medical_specialtymedicine.drug_mechanism_of_actionSildenafilVasodilator AgentsPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeNitric OxidePolymerase Chain ReactionPiperazinesSildenafil CitrateAcetylcysteinechemistry.chemical_compoundInternal medicineSmokeparasitic diseasesTobaccomedicineHumansSulfonesEndothelial dysfunctionPhosphodiesterase inhibitorLungCells CulturedDNA PrimersbiologyBase Sequencebusiness.industrymedicine.diseaseEndothelial stem cellEndocrinologychemistryEnzyme inhibitorPurinescardiovascular systembiology.proteinEndothelium VascularbusinessPhosphodiesterase 5 inhibitorOxidative stressmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

2020

Background. Anticoagulant therapy, the cornerstone treatment in acute venous thromboembolism (VTE), strongly impacts thrombin generation (TG). Until now, the appearance of the TG curve in platelet rich plasma (PRP) from patients with acute VTE has not been investigated. Methods. We analyzed the shape of TG curves measured in PARP of 180 acute VTE patients. Results. Normal shape of TG curves was observed in 110 patients, 50 patients showed no TG and 20 patients showed biphasic TG curve. The linear regression analysis, adjusted for age, sex, VTE clinical phenotypes and therapy showed that the appearance of biphasic curves is significantly associated with female sex, presence of cancer and the…

medicine.medical_specialtymedicine.drug_mechanism_of_actionbusiness.industryFactor Xa InhibitorCancerGeneral Medicinemedicine.diseaseGastroenterologyThrombin generationPlatelet-rich plasmaInternal medicinemedicineClinical significanceCurve shapePlateletcardiovascular diseasesbusinessVenous thromboembolismJournal of Clinical Medicine
researchProduct